Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Nurix Therapeutics (NRIX) over the last 5 years, with Q4 2025 value amounting to -$0.83.

  • Nurix Therapeutics' EPS (Weighted Average and Diluted) fell 1066.67% to -$0.83 in Q4 2025 from the same period last year, while for Nov 2025 it was -$3.05, marking a year-over-year decrease of 553.63%. This contributed to the annual value of -$3.05 for FY2025, which is 590.28% down from last year.
  • Nurix Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.83 in Q4 2025, which was down 1066.67% from -$1.03 recorded in Q3 2025.
  • Nurix Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.45 during Q2 2023, with a 5-year trough of -$1.03 in Q3 2025.
  • For the 5-year period, Nurix Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.76, with its median value being -$0.75 (2023).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 6833.33% in 2022, then surged by 5544.55% in 2023.
  • Over the past 5 years, Nurix Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.85 in 2021, then decreased by 1.18% to -$0.86 in 2022, then grew by 10.47% to -$0.77 in 2023, then rose by 2.6% to -$0.75 in 2024, then fell by 10.67% to -$0.83 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.83 for Q4 2025, versus -$1.03 for Q3 2025 and -$0.52 for Q2 2025.